Australia markets closed
  • ALL ORDS

    7,713.10
    -32.80 (-0.42%)
     
  • AUD/USD

    0.6947
    +0.0057 (+0.82%)
     
  • ASX 200

    7,504.10
    -34.90 (-0.46%)
     
  • OIL

    75.54
    +1.43 (+1.93%)
     
  • GOLD

    1,889.00
    +9.50 (+0.51%)
     
  • BTC-AUD

    33,039.09
    -55.48 (-0.17%)
     
  • CMC Crypto 200

    527.08
    +1.94 (+0.37%)
     

A AFT Pharmaceuticals Limited (NZSE:AFT) insider increased their holdings by 16% last year

Looking at AFT Pharmaceuticals Limited's (NZSE:AFT ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

Check out our latest analysis for AFT Pharmaceuticals

The Last 12 Months Of Insider Transactions At AFT Pharmaceuticals

In the last twelve months, the biggest single purchase by an insider was when Independent Director Jon Lamb bought NZ$171k worth of shares at a price of NZ$4.20 per share. That means that even when the share price was higher than NZ$3.70 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Jon Lamb was the only individual insider to buy shares in the last twelve months.

Jon Lamb bought 55.67k shares over the last 12 months at an average price of NZ$4.26. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Does AFT Pharmaceuticals Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. AFT Pharmaceuticals insiders own 70% of the company, currently worth about NZ$274m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Do The AFT Pharmaceuticals Insider Transactions Indicate?

There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. Judging from their transactions, and high insider ownership, AFT Pharmaceuticals insiders feel good about the company's future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 1 warning sign for AFT Pharmaceuticals and we suggest you have a look.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here